Literature DB >> 1571657

The cholesterol controversy.

J A Tobert.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1571657      PMCID： PMC1881553          DOI： 10.1136/bmj.304.6828.713

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  4 in total

1.  Should there be a moratorium on the use of cholesterol lowering drugs?

Authors:  G Davey Smith; J Pekkanen
Journal:  BMJ       Date:  1992-02-15

2.  Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B.

Authors:  G Brown; J J Albers; L D Fisher; S M Schaefer; J T Lin; C Kaplan; X Q Zhao; B D Bisson; V F Fitzpatrick; H T Dodge
Journal:  N Engl J Med       Date:  1990-11-08       Impact factor: 91.245

3.  Long-term safety and efficacy profile of simvastatin.

Authors:  S J Boccuzzi; T S Bocanegra; J F Walker; D R Shapiro; M E Keegan
Journal:  Am J Cardiol       Date:  1991-11-01       Impact factor: 2.778

4.  Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia.

Authors:  R H Bradford; C L Shear; A N Chremos; C Dujovne; M Downton; F A Franklin; A L Gould; M Hesney; J Higgins; D P Hurley
Journal:  Arch Intern Med       Date:  1991-01
  4 in total
  3 in total

1.  Should clofibrate still be prescribed?

Authors:  M G Dunnigan
Journal:  BMJ       Date:  1992-08-15

2.  Cholesterol lowering and mortality: the importance of considering initial level of risk.

Authors:  G D Smith; F Song; T A Sheldon
Journal:  BMJ       Date:  1993-05-22

3.  All cholesterol-lowering interventions are expected to reduce stroke: Confirmatory data from IMPROVE-IT.

Authors:  Raffaele De Caterina; Tanya Salvatore; Roberto Marchioli
Journal:  Data Brief       Date:  2016-04-27
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.